The headline numbers are striking. Between 1991 and 2024, the overall cancer death rate in the United States fell by 35 percent, an achievement the report attributes to reductions in smoking rates combined with advances in prevention, early detection, and treatment. That decline translates into 4.8 million fewer cancer deaths over the period. Survival gains are increasingly extending even to patients with advanced and metastatic disease: the five-year relative survival rate for distant-stage cancers of all types has more than doubled over the past three decades, rising from 17 percent in the mid-1990s to 36 percent during 2016 to 2022. Those figures, the report argues, are the direct product of sustained federal investment in the National Institutes of Health, the National Cancer Institute, the Food and Drug Administration, and the Centers for Disease Control and Prevention.

The regulatory pipeline tells a similar story of momentum. From July 1, 2025, to June 30, 2026, the FDA approved 11 new anticancer therapeutics, several of which marked historic firsts. Among them was the first molecularly targeted therapy for a rare, aggressive brain tumor driven by a specific genetic alteration, and the first approval of a proteolysis-targeting chimera, a novel class of drug that hijacks the cell’s own protein degradation machinery to destroy cancer cells, indicated for patients with breast cancer. The agency also greenlit the first immune checkpoint inhibitor for ovarian cancer and the first chimeric antigen receptor T-cell therapy for patients with marginal zone lymphoma, extending a living-drug approach once confined to a handful of blood cancers.

Beyond new molecules, the FDA expanded the uses of five previously approved anticancer therapeutics and cleared a series of devices and tools that signal where clinical care is heading. These included a wearable, noninvasive device for treating pancreatic cancer, an at-home human papillomavirus self-collection kit designed to widen access to cervical cancer screening, and several artificial intelligence-based tools intended to improve the early detection and diagnosis of cancers. Taken together, the approvals sketch a regulatory environment increasingly receptive to technologies that move diagnosis out of the clinic and into patients’ homes and that embed computational analysis into routine imaging and pathology.

Artificial intelligence features prominently in the report’s survey of new frontiers. Researchers have recently combined AI with advanced spatial imaging technologies to generate high-resolution maps of tumors, revealing how cancer and immune cells are organized and interact within the tumor microenvironment, knowledge that could guide the design of more effective immunotherapies. In drug development, one recently described AI model screened approximately 10,000 human proteins against more than 500 million compounds, identifying more than 2 million candidate molecules for further study, a scale of exploration unattainable through conventional laboratory screening alone. The report also notes that AI is improving the interpretation of routine medical images and the analysis of complex digital pathology slides, capabilities reflected in the recent FDA approvals of AI-assisted devices, and that AI-driven tools are helping clinicians predict outcomes, personalize treatment plans, and design better clinical trials, while potentially easing burnout among health care providers.

Cancer vaccines, long a tantalizing but elusive goal, are described as gaining real clinical traction. A small individualized pancreatic cancer vaccine trial has produced durable remissions in patients, including Donna Gustafson, one of several patients whose personal stories are woven through the report. In melanoma, patients with high-risk disease who received an individualized mRNA neoantigen vaccine alongside immunotherapy after surgery experienced sustained improvements in recurrence-free and distant metastasis-free survival compared with immunotherapy alone. For early-stage triple-negative breast cancer, an individualized mRNA vaccine generated durable neoantigen-specific T-cell responses, with most patients remaining relapse-free for up to six years after vaccination. A preventive strategy is also under exploration: an mRNA-based vaccine called Nous-209, designed to provoke immune responses against cells carrying Lynch syndrome-associated mutations, was found in a small trial to be safe, free of serious side effects, and capable of triggering a strong, durable immune response in people with the inherited condition.

The report also examines a question now hovering over primary care: whether the hugely popular GLP-1 weight loss drugs might reduce cancer risk. The evidence is genuinely mixed. One recent study found that semaglutide, sold as Ozempic and Wegovy, was associated with a 12 percent reduction in obesity-related cancer risk. A separate study of individuals with type 2 diabetes found that GLP-1 use was associated with a 40 percent lower risk of esophageal cancer and a 46 percent lower risk of colorectal cancer compared with insulin therapy, and other analyses suggest possible reductions in the risk of skin, breast, prostate, hematologic, and some gynecologic cancers. Yet a large review of 48 clinical trials involving more than 94,000 participants treated with GLP-1s found no significant reduction in the overall risk of obesity-related cancers, and some studies point in the opposite direction: liraglutide use was associated with a 70 percent increased risk of thyroid cancer and a 62 percent increased risk of respiratory cancer. The report’s verdict is cautious: the preventive role of these drugs, while promising, requires further investigation.

Against the progress, the report sets a sobering accounting of the disease’s continuing burden. In 2026, an estimated 2.1 million new cancer cases will be diagnosed in the United States, and more than 626,000 people will die from cancer. By 2050, annual new cases are projected to surpass 2.5 million, a 19 percent increase. Survival remains starkly unequal across tumor types: between 2016 and 2022, five-year relative survival was 13.7 percent for pancreatic cancer and just 6.6 percent for glioblastoma, an aggressive brain cancer, compared with 91.9 percent for female breast cancer and 98.2 percent for prostate cancer. The report also flags the rise of early-onset cancers, diagnosed in people aged 18 to 49, as a pressing public health concern. Globally, cancer incidence among people under 50 increased by nearly 80 percent between 1990 and 2019, with gastrointestinal cancers such as colorectal, stomach, and esophageal cancers contributing disproportionately. Researchers cite overlapping drivers including rising obesity, sedentary lifestyles, greater exposure to environmental pollutants, and shifts in dietary patterns.

The economic stakes are equally large. Direct costs of cancer care in the United States, many borne by patients themselves, were estimated at more than $236 billion in 2020, and one analysis cited in the report projects that cancer will cost the U.S. economy $5.3 trillion over the next three decades once indirect costs and lost productivity are included. It is against that backdrop that the AACR issues its policy demands. Most urgently, the organization calls on Congress to permanently block a proposed Office of Management and Budget rule, Regulation for Federal Financial Assistance, which the report warns would inject political considerations into funding decisions and broaden agencies’ authority to terminate grants for reasons unrelated to scientific merit. Bipartisan action has blocked the rule through December 11, 2026, but the report argues a temporary delay is not a lasting solution.

The Call to Action lays out specific asks: at least $51.303 billion for the NIH and at least $7.999 billion for the NCI in fiscal year 2027; protection of the cancer research workforce; preservation of scientific merit as the sole foundation of federal funding decisions; safeguards for active research awards and clinical trials; protection of researchers’ ability to publish and share findings; and risk-based, proportionate oversight of international collaboration. It further urges strengthening the FDA’s capacity to translate discoveries into patient benefits, sustaining evidence-based public health programs, modernizing interoperable data infrastructure, and removing barriers to prevention, screening, clinical trial participation, and survivorship care. AACR President Keith Flaherty, a physician-scientist who chaired the report’s steering committee, said advances in genomics, immunology, and artificial intelligence have given researchers more insight than ever into the complexities of cancer and are enabling treatments that precisely match each patient’s disease. Chief Executive Officer Margaret Foti added that decades of robust federal investment have transformed patient care and saved millions of lives, and that only by sustaining meritorious research free of political interference will the next generation of lifesaving breakthroughs emerge.

Subject of Research: Annual assessment of cancer research progress, FDA approvals, emerging technologies, and federal funding policy

Article Title: AACR releases annual cancer progress report highlighting promising advances for patients

Article References: AACR releases annual cancer progress report highlighting promising advances for patients. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: AACR, cancer progress report, FDA approvals, cancer mortality, immunotherapy, cancer vaccines, mRNA vaccines, artificial intelligence, GLP-1 receptor agonists, early-onset cancers, NIH funding, cancer screening

Multiple myeloma is a malignancy rooted in plasma cells within the bone marrow, often preceded by a clinically silent phase termed smoldering multiple myeloma. Characterized by an abnormal accumulation of precursor plasma cells without overt symptoms, high-risk SMM bears a grim prognosis, with approximately half of patients progressing to full-fledged myeloma within two years. The challenge has long been to intercept this progression effectively while minimizing toxicities—a therapeutic gap CAR T-cell technologies are poised to fill.

The CAR-PRISM trial targeted B-cell maturation antigen (BCMA), a transmembrane protein expressed on pathological plasma cells and an established CAR T-cell target. The investigational therapy, ciltacabtagene autoleucel (cilta-cel), previously FDA-approved in 2024 for relapsed multiple myeloma, was administered to twenty patients diagnosed with high-risk smoldering multiple myeloma according to stringent inclusion criteria grounded in the 20/2/20 rule—percentages of bone marrow plasma cells, serum M-protein levels, and involved/uninvolved light chain ratios signaling elevated progression risk.

A critical innovation of this trial was administering cilta-cel before patients underwent exposure to conventional induction chemotherapy, hypothesizing that earlier intervention in a lower disease burden setting would potentiate more effective immune-mediated tumor destruction. This approach leveraged the intactness of patients’ immune functionality at this nascent stage of transformation to maximize CAR T-cell expansion, persistence, and antitumor activity.

Over a median follow-up of 15.3 months, all treated patients achieved stringent minimal residual disease (MRD) negativity—the deepest measurable level of cancer eradication—within two months post-infusion. Importantly, sustained MRD-negative status was observed with no evidence of disease relapse or mortality, signaling profound and lasting remissions. Some individuals were monitored beyond 18 months, reaffirming the durability of responses, an outcome never before realized at this disease phase using CAR T-cells.

Safety outcomes also underscored the feasibility of this method. The study observed no dose-limiting toxicities or high-grade adverse events, common concerns with CAR T-cell therapies in more advanced, heavily pretreated patients. Cytokine release syndrome (CRS), a frequent immune-related side effect, manifested only in low-grade, manageable forms, with zero cases of severe CRS or neurotoxicity. Transient hematologic toxicities were the most prevalent adverse events, alongside reversible cases of mild-to-moderate neurological symptoms in a subset of patients.

These clinical outcomes strongly align with the underlying hypothesis that CAR T-cell efficacy is enhanced when tumor burden and immunosuppressive microenvironmental factors are minimized. Early interception allows for robust expansion of engineered T-cells in an immunologically hospitable milieu, promoting sustained surveillance and destruction of malignant precursors before they evolve resistance or compromise host immunity.

The CAR-PRISM trial’s success opens avenues for redefining therapeutic paradigms in smoldering multiple myeloma, where the prevailing standard has been watchful waiting until clinical progression demands intervention. The dramatic remission rates reported here suggest that early, definitive immunotherapy could recalibrate management strategies toward durable remissions or even potential cure.

Beyond CAR T-cell therapy, the Dana-Farber team is actively investigating complementary immunotherapeutic approaches, including bispecific antibodies, which simultaneously bind T-cells and tumor antigens to harness endogenous immunity against myeloma precursors. This multipronged immunotherapy research initiative aims to optimize long-term disease control and enhance patient outcomes in early multiple myeloma stages.

Ongoing mechanistic studies are delving into the molecular and immunologic distinctions underlying responses in high-risk SMM compared to relapsed myeloma cases. Insights from these comparisons may reveal biomarkers predictive of CAR T-cell efficacy and inform dosage modulation to further enhance therapeutic windows.

It is also notable that daratumumab, a CD38-targeting monoclonal antibody, gained FDA approval in late 2025 as the first treatment for high-risk smoldering multiple myeloma, marking a paradigm shift from monitoring to proactive intervention. However, CAR T-cell therapy delivers the potential advantage of a one-time, potentially curative infusion, circumventing repeated administrations and chronic toxicities.

Looking ahead, researchers caution that longer-term follow-up and larger multi-center studies are necessary to validate durability and reproducibility. Nevertheless, this trial’s promising safety profile and robust responses provide a new beacon of hope for patients at the cusp of multiple myeloma diagnosis and highlight Dana-Farber’s commitment to translational innovation.

Dr. Omar Nadeem, clinical director of Dana-Farber’s Myeloma Immune Effector Cell Therapy Program, summarized the impact poignantly: “Our early intervention strategy using CAR T-cell therapy has achieved what many thought unattainable—rapid and deep clearance of disease at the earliest detectable stage. This is a transformative milestone that could reimagine cancer interception for millions facing high-risk smoldering myeloma.”

As the oncology field embraces personalized immunotherapy’s full potential, the CAR-PRISM study exemplifies how integrating precise molecular criteria and cutting-edge cellular products can deliver breakthroughs that may ultimately defeat complex hematologic malignancies at their inception.

Subject of Research: Chimeric Antigen Receptor (CAR) T-cell therapy for high-risk smoldering multiple myeloma

Article Title: Dana-Farber’s Phase 2 CAR-PRISM Trial Demonstrates Deep and Durable Responses in Early-Stage Multiple Myeloma

News Publication Date: April 20, 2026

Web References:
https://www.dana-farber.org/find-a-doctor/omar-nadeem
https://www.dana-farber.org/find-a-doctor/irene-ghobrial
https://labs.dana-farber.org/ghobriallab/people/david-cordas-dos-santos-md
https://www.nature.com/articles/s41591-026-04365-y

References:
Nadeem, O. et al. (2026) “Deep and lasting responses to CAR T-cell therapy in high-risk smoldering multiple myeloma,” Nature Medicine, DOI:10.1038/s41591-026-04365-y

Image Credits: Courtesy of Dana-Farber Cancer Institute

Keywords:
CAR T-cell therapy, smoldering multiple myeloma, minimal residual disease, cilta-cel, B-cell maturation antigen, immunotherapy, hematologic malignancies, cytokine release syndrome, bispecific antibodies, FDA approval, cancer interception, early-stage myeloma